Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]

"Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]." ImmunoTargets and Therapy, , pp. 77–78

Acknowledgments

Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing/editorial assistance was provided by Iulia Oprea, MD, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.

Disclosure

Simmi Wiggins is a Sanofi employee and may hold stock and/or stock options in the company; Noah A. Levit was a Regeneron Pharmaceuticals Inc. employee and shareholder at the time this letter was written and reports compensation as non-promotional speaker from Sanofi, outside the submitted work.